Titian Software signs a three-year deal with a top life science company. The Mosaic software arrangement makes it simple to expand Evotec’s systems and fosters future expansion.
Olivier Casamitjana of Evotec and David Booth of Titian Software
Pictured are Olivier Casamitjana, senior vice president and head of global compound management at Evotec, and David Booth, director of major accounts for Europe at Titian Software. Please click here to download the image.
London, UK (August 1, 2023) – Newswire for Life Sciences – The leading provider of sample management software for the life sciences, Titian Software LTD, and the life science firm Evotec have agreed to a three-year extension of their partnership centred on Titian Software’s Mosaic Sample Management Platform. Mosaic is a component of Evotec’s ambitions to bolster its growing offerings by enhancing sample management across the company. The new contract offers unrestricted
Senior Vice President and Global Compound Management Head at Evotec, Olivier Casamitjana, stated: “This agreement aligns Titian as a solution provider with our plans to expand our business further, enabling easy extension of Evotec’s systems and ensuring Titian can respond dynamically to our operational needs.”
For nearly 20 years, Evotec has used Mosaic software for sample administration and tracking. This is not the first project that Evotec and Titian have worked on together. Past projects have included the co-development of ground-breaking technologies like acoustic dispensing workflows and, more recently, the synchronisation of inventory across organisations so that Evotec can securely share real-time inventory information and shipment updates with each customer. Version 9.0 of the Mosaic programme includes this latter capability.
Titian Software’s CEO, Nicholas Spurrett,
Regarding Evotec SE
The objective of Evotec, a life science company with a distinctive business strategy, is to find and create highly efficient treatments and make them accessible to patients. For the research, development, and production of first-in-class and best-in-class pharmaceutical goods, the Company’s multimodality platform combines a special assortment of cutting-edge technologies, data, and science. Evotec uses its “Data-driven R&D Autobahn to Cures” for its own initiatives and in collaboration with a network of partners that includes all 20 of the largest pharmaceutical companies, more than 800 biotechnology firms, academic institutions, and other healthcare stakeholders. Evotec has strategic initiatives in a variety of therapeutic areas that are currently neglected, such as neurology, oncology, metabolic illnesses, and infectious diseases. Evotec seeks to excel in these fields.
